Novartis Exelon Patch Patent Battle: PTAB Can Disagree With District Court
Executive Summary
Federal Circuit rejects Novartis argument that Patent Trial and Appeal Board unlawfully concluded Exelon patents were unpatentable after a district court upheld them.
You may also be interested in...
Will Inter Partes Review Go Away? Supreme Court Weighs Fate
Biopharma and generic industries stand on opposing sides in case that could eliminate the patent challenge proceeding. Interactive timeline covers IPR's five-year history leading to oral arguments Nov. 27.
PTAB Tosses Two More Humira Patents; Will Supreme Court Eliminate IPR Proceeding?
Patent Trial and Appeal Board rules for Coherus in its challenge of Humira patents and takes up review of Cialis patent. US high court to consider constitutionality of inter partes review proceeding.
PTAB Finds Favor In Court; Novartis Is Latest To Strike Out In Challenge
Federal Circuit affirms US Patent Trial and Appeal Board decision against Gilenya composition patent a week after upholding board decision on Exelon Patch patents; court has reviewed 200 PTAB decisions and affirmed 158 of them.